10.1016/s1470-2045(21)00034-6 - Alpelisib plus fulvestrant in PIK3CA-...

This document has been corrected

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

10.1016/s1470-2045(21)00034-6

Published Online: 2021-04-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: Aleix Prat•Christina Arce•Dejan Juric•Eva Ciruelos•Florence Lerebours•Hemanth Kanakamedala•Hope S Rugo•Juan Pablo Zarate•Manuel Ruiz-Borrego•Nicholas Turner•Nickolas Sophos•Pamela Drullinsky•Patrick Neven•Stephen Chia•Stuart Turner•Thomas Bachelot•Wei-Chun Hsu•Yeon Hee Park•Yu-Ming Shen

This document has been corrected

10.1016/s1470-2045(21)00034-6

Published Online: 2021-04-?

Journal: The Lancet Oncology

NOW

2024-12-01•Erratum

Retraction and republication—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

10.1016/s1470-2045(24)00647-8